Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Northern lights chances rise for Christmas as space weather remains unsettled - 2Palestine weekly wrap: Protests sweep West Bank after death penalty law
- 3French ship crosses Strait of Hormuz in first Western European transit during Iran war
- 4Become the best at Discussion: 6 Procedures for Progress
- 5Figure out How to Plan for Your Web-based Degree monetarily
- As her kidneys fail and time runs short, this activist fights to decriminalize euthanasia in Mexico
- California warns of death cap mushrooms outbreak resulting in 3 deaths
- Iranian missile hit on Ne'ot Hovav factory leads to fear of chemical leakage
- Figure out How to Streamline Eco-friendliness in Your Volvo XC40
- French rapper Gims placed under investigation for 'aggravated money laundering'
- Oprah Winfrey's Favorite Wellness Destination Is A Luxurious Italian Retreat
- Best Amusement Park in Europe: Where Do You Very much want to Visit?
- Kate Hudson, 46, says she doesn't need long workouts to feel good
- Bad flu season getting worse; skyrocketing cases set state record
